On February 6, 2026, Aspire Biopharma Holdings, Inc. signed a securities purchase agreement to issue 25,000 shares of Series A Convertible Preferred Stock for up to $11 million, convertible to common stock at a specified price. The offering may involve a second closing for an additional $10 million pending conditions and stockholder approval.